Unknown
MDPI - Multidisciplinary Digital Publishing Institute
Publication Date:
2023-02-02
Description:
This reprint examines regulatory, pricing and reimbursement issues related to the market access and uptake of off-patent biologics, biosimilars, next-generation biologics and competing innovative medicines in European countries.
Keywords:
infliximab
;
etanercept
;
TNFα inhibitors
;
biologics
;
biosimilars
;
Germany
;
policies
;
incentives
;
uptake
;
market dynamics
;
biosimilar market
;
biosimilar/supply and distribution
;
biosimilar sustainability
;
Delphi technique
;
pricing
;
reimbursement
;
utilization
;
biosimilar
;
biological
;
information
;
education
;
communication
;
patient
;
Europe
;
adalimumab
;
biosimilarity assessment
;
quality attributes (QAs)
;
potentially critical quality attributes (pCQAs)
;
European public assessment reports (EPARs)
;
clinical governance
;
Spain
;
barriers
;
regulatory
;
review
;
approval
;
clinical
;
queries
;
regulatory science
;
budget impact analysis
;
savings
;
pharmaceutical spending
;
cost containment
;
reference biological
;
competitive market
;
Belgium
;
trastuzumab
;
intravenous
;
subcutaneous
;
HER2-positive breast cancer
;
drug costs
;
healthcare costs
;
cost simulation
;
tender
;
procurement
;
off-patent
;
award criteria
;
switching
;
interchangeability
;
sustainability
;
competition
;
n/a
;
bic Book Industry Communication::M Medicine
;
bic Book Industry Communication::K Economics, finance, business & management::KN Industry & industrial studies::KND Manufacturing industries::KNDP Pharmaceutical industries
Language:
English
Format:
image/jpeg
|
Location |
Call Number |
Expected |
Availability |
